Table 3.
Presentation, latency, and neonatal morbidity by specific tocolytic regimen.
| Tocolytic Regimen |
n | Median (IQR) Gestational Age at Presentation (weeks) |
Median (IQR) Cervical Dilation at Presentation (centimeters) |
Median (IQR) Gestational Age at Delivery (weeks) |
Latency of >= 48 hours (n, %) |
Major neonatal morbidity (n, %) |
|---|---|---|---|---|---|---|
| No tocolysis | 64 | 29.8 (27.6 – 31.1) |
6 (4.5 – 6.5) |
29.9 (27.9 – 31.2) |
5 (7.8) | 28 (43.8) |
| Nifedipine Only | 32 | 30.2 (28.4 – 31.1) |
5 (4 – 6.5) |
30.4 (28.5 – 31.9) |
4 (12.5) | 11 (34.4) |
| Magnesium Sulfate Only | 72 | 29.3 (26.1 – 31.0) |
5 (4 – 6) |
29.7 (26.1 – 31.1) |
17 (23.6)* | 30 (41.7) |
| Indomethacin Only | 19 | 28.3 (26.2 – 30.4) |
4.5 (4 – 6)* |
28.3 (26.3 – 30.4) |
3 (15.8) | 10 (52.6) |
| Magnesium Sulfate and Indomethacin | 43 | 28.4 (25.7 – 30.4) |
4.5 (4 – 5)* |
28.9 (25.7 – 30.9) |
10 (23.3)* |
22 (51.1) |
| Magnesium Sulfate and Nifedipine | 27 | 27.8 (25.3 – 30.3)* |
4 (4 – 5.5)* |
29.9 (26.0 – 31.9) |
11 (40.7)* |
8 (29.3) |
| Nifedipine and indomethacin | 18 | 27.7 (26.3 – 29.6) |
4 (4 – 5)* |
28.4 (26.3 – 30.7) |
4 (22.2) | 10 (55.6) |
| Nifedipine, indomethacin, and magnesium sulfate | 22 | 28.7 (26.5 – 30.4) |
4 (4 – 5)* |
29 (26.7 – 31.7) |
6 (27.3)* | 6 (27.3) |
| P-value | 0.161 | <0.001 | 0.348 | 0.023 | 0.317 | |
*
indicates p<0.05 in pairwise comparison with ‘no tocolysis’ group as referent.